Jazz Pharmaceuticals (JAZZ) Goldman Sachs 45th Annual Global Healthcare Conference summary

Financial performance and outlook

• Achieved 12% combined growth in major products and 13% growth in oncology year-over-year in Q1 2024.

• XYWAV, the largest product, grew 14% year-over-year; revenue guidance for 2024 is $4–$4.2 billion, targeting 7% growth at midpoint.

• Ended Q1 with $1.8 billion in cash and $267 million in operating cash flow.

• Confident in meeting full-year guidance and continuing strong financial performance.

Commercial and product portfolio updates

• XYWAV maintains a strong position in narcolepsy and idiopathic hypersomnia, with a sustainable growth outlook and over 12,950 patients treated in Q1.

• EPIDIOLEX is on track to become a blockbuster by 2025, with growth in both U.S. and international markets and significant new data supporting efficacy.

• Royalty income from AG versions of XYREM expected to exceed $200 million in 2024.

R&D pipeline and milestones

• Zanidatamab received FDA priority review for second-line BTC, with a PDUFA date set for November 29, and MAA filed in Europe.

• Positive mature data for zanidatamab in BTC: 15.5 months OS overall, 18.1 months in IHC 3+; GEA frontline study readout expected by year-end.

• Phase III trial for EPIDIOLEX in Japan to report top-line data in H2 2024, targeting a 20,000-patient market.

• Suvecaltamide phase IIb trial in Essential Tremor to read out imminently, with a robust 400-patient design.

• Zepzelca frontline trial with Tecentriq to read out late 2024 or early 2025.